Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Natural killer (NK) cell education requires ligands to bind to inhibitory NK cell receptor (iNKR), which is very important for producing self-tolerant functional NK cells. The main family of inhibitory NK cell receptors is inhibitory KIRs (iKIRs), which interact with their HLA class I ligands to play an important role in NK cell regulation and protect normal tissues from NK cell attack. To enhance the anti-tumor efficacy of NK cells, we optimized these unique activated NK cells, which lack KIR inhibitory receptors while retaining a wide range of activated receptors that enable selectively target and kill tumor cells.
The panoply of activating and inhibiting receptors on NK cells and the myriad mechanisms by which NK cells mediate cytotoxicity provide ample opportunities to engineer NK cells using genetic methods aimed at making signal balance tend to be activated. Our unique NK cell platform has been produced and used as a cell-based "off the shelf" therapy in clinical trials and has proven its potential to kill cancer.
Unlike normal NK cells, our unique K-NK cells do not express iKIRs, which are often used by diseased cells to escape the killing function of NK cells. These unique activated NK cells are optimized to retain a wide range of activated receptors while lacking KIR inhibitory receptors, which can selectively target and kill diseased cells. K-NK cells also carry larger granzymes and perforin-containing particles, allowing them to provide a larger payload of lethal enzymes to multiple targets. Encouraging evidence of safety, mobility and prolonged survival have been proven.
Fig.1 NK cell engineering strategies to enhance NK cell cytotoxicity against tumors.
Off-the-Shelf
A universal cell-based therapy that does not require personalized patient matching.
Eliminate a Step
No need to collect the patient's white blood cells. With off-the-shelf aNK, this invasive procedure is eliminated.
Dosing Control
K-NK's clearance and multiple dosing may reduce the risk of adverse events, thereby producing a favorable safety profile.
Cost Effective
Economical cell therapy treatment for cancer patients aNK can be produced in large multi-dose batches.
Notably, as the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs provides one-stop services for CAR-NK therapy development, including but not limited to:
If you are interested in our services, please send an email to contact us, and our team will get back to you as soon as possible.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
